摘要
目的:研究降脂颗粒(Jiangzhi Granule,JZG)对非酒精性脂肪性肝病(non-alcoholic fatty liverdisease,NAFLD)大鼠肝X受体α(liver X receptorα,LXRα)和固醇调节元件结合蛋白1c(sterol regulatory element-binding protein-1c,SREBP-1c)表达的影响。方法:雄性Wistar大鼠40只随机分成正常组、模型组、吡格列酮(pioglitazone,PIO)组和JZG组,每组各10只。正常组给予普通饲料,模型组、PIO组及JZG组给予高脂饲料(88%普通饲料+10%猪油+2%胆固醇)。造模4周后药物干预4周,留取肝脏组织,苏木精和伊红染色进行病理学观察,并检测肝组织三酰甘油(triacylglycerol,TAG)和游离脂肪酸(free fatty acid,FFA)水平;腹主动脉采血,检测血清丙氨酸氨基转移酶(alanine aminotransferase,ALT)和天冬氨酸氨基转移酶(aspartate aminotransferase,AST)活性;实时聚合酶链式反应法检测肝组织LXR-α和SREBP-1c mRNA表达;蛋白质印迹法检测肝组织LXRα和SREBP-1c的表达。结果:模型大鼠肝组织出现明显的大泡性脂肪变性,JZG可显著降低模型大鼠血清ALT和AST水平,JZG与PIO均可降低模型大鼠肝组织FFA、TAG含量及LXRα、SREBP-1c的表达水平。结论:JZG可调节模型大鼠脂肪酸代谢紊乱,其作用可能与下调肝组织LXRα和SREBP-1c的表达有关。
Objective： To study the effects of Jiangzhi Granule （JZG）, a compound traditional Chinese herbal medicine, in regulating liver X receptor α （LXRα） and sterol regulatory element-binding protein-1c （SREBP-1c） expressions in a rat model of non-alcoholic fatty liver disease （NAFLD）.Methods： Forty specific pathogen-free Wistar male rats were randomly divided into normal group, untreated group, pioglitazone （PIO） group and JZG group. All rats were fed with high-fat diet （88% normal chow plus 10% lard plus 2% cholesterol） for 4 weeks except for the normal group. After the NAFLD model was established, PIO and JZG were fed to rats in the corresponding groups respectively for another 4 weeks. At the end of the 8th week, liver steatosis level was observed under a light microscope with hematoxylin and eosin （HE） staining; serum alanine aminotransferase （ALT） and aspartate aminotransferase （AST） activities and triacylglycerol （TAG） and free fatty acid （FFA） contents in liver tissues were measured. LXRα and SREBP-1c expressions in liver tissues were determined by real-time polymerase chain reaction and Western blot methods.Results： Compared with the normal group, there were physiological changes for hepatic steatosis in liver tissues in the untreated group as observed by HE staining. JZG improved serum ALT and AST levels which were significantly increased in the untreated group. Both JZG and PIO improved FFA and TAG levels in liver tissues which were significantly increased in the untreated group. mRNA and protein levels of LXRα and SREBP-1c in the untreated group were higher than those in the normal group, while the treatment of JZG and PIO lowered their expressions.Conclusion： JZG may regulate fatty acid metabolic disorder by decreasing the levels of LXRα and SREBP-1c.
出处
《中西医结合学报》
CAS
2011年第9期998-1004,共7页
Journal of Chinese Integrative Medicine
基金
国家自然科学基金资助项目(No.81001508)
上海市优秀学科带头人计划资助项目(No.09XD1403800)
上海市教育委员会重点学科资助项目(No.J50305
E3008)
上海市教育委员会预算内资助项目(No.09J W23)
上海高校创新团队建设项目(第一期)
关键词
脂肪肝
降血脂药(中药)
中草药
肝X受体Α
胆固醇调节元件结合蛋白1
大鼠
fatty liver
antilipemic agents （TCD）
drugs
Chinese herbal
liver X receptor α
sterol regulatory element-binding protein-1
rats
